摘要
目的观察恶性淋巴细胞增殖性疾病患者血清可溶性细胞间粘附分子1(sICAM1)水平的变化及其与病情、疗效的关系。方法采用亲合素和生物素标记的酶联免疫法,对多发性骨髓瘤(MM)、恶性淋巴瘤(ML)及急性淋巴细胞白血病(ALL)患者化疗前后血清sICAM1水平进行检测。结果22例MM患者中9例(41%)、32例非霍奇金淋巴瘤(NHL)患者中17例(53%)、19例ALL患者中12例(63%)的血清sICAM1水平高于正常。血清sICAM1水平,MM患者中受C反应蛋白和β2微球蛋白为依据的Bataile分期的影响,与Durie分期无关;NHL患者中,与病理类型、AnnArbor分期、B症状有关,与血清乳酸脱氢酶无关;ALL患者中,合并中枢神经系统白血病者明显高于未合并者。血清sICAM1升高者与血清sICAM1正常者比较,前者疗效较差。动态观察发现,随着病情缓解,血清sICAM1水平亦降至正常。结论血清sICAM1水平的检测有助于判断患者的病情及疗效。
Objective To investigate the
correlation of serum levels of soluble intercellular adhesion molecule 1 (sICAM1) with clinical
situation and treatment outcome in lymphoproliferative disorders. Methods Serum sICAM1
levels were measured by immunoenzymetic assay. Results Pretreatment serum sICAM1
levels were above normal in 41% (9/22) of multiple myeloma (MM), 53% (17/32) of nonHodgkins
lymphoma (NHL) and 63% (12/19) of acute lymphocytic leukemia (ALL) patients. Serum sICAM1
levels in MM were positively correlated with Bataille stages, but were not related to Durie
stage. Meanwhile, sICAM1 levels in NHL were associated with the category of pathology, Ann
Arbor stage and B symptom, but were not related to serum LDH levels. sICAM1 levels were
significantly higher in ALL patients complicated with central nervous system leukemia (CNSL)
than in those without CNSL. Patients with elevated serum sICAM1 levels had poorer treatment
outcomes. Serum sICAM1 levels were returned to normal at remission. WTHZ]Conclusion
Measurement of serum sICAM1 levels in lymphoproliferative disorders patients is helpfull for
judging the clinical status and treatment outcome.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1999年第5期232-234,共3页
Chinese Journal of Hematology
关键词
多发性骨髓瘤
淋巴瘤
白血病
SICAM-1
Multiple
myelomaLymphomaLeukemia,
lymphocytic, acuteIntercellular adhesion molecule 1